Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
While FDA has approved Lynparza (also known as olaparib) to treat ovarian and related cancers in women who carry mutations in BRCA1 or BRCA2, and who have received three or more chemotherapy treatments, PARP inhibitors are not currently FDA-approved for treating breast cancer. However, many open clinical trials are studying PARP inhibitors for treating breast cancer. Preliminary research looking at lynparza in breast cancer has been promising and trials are ongoing.
The OlympiAD study is a phase III clinical trial that will study the efficacy and safety of lynparza monotherapy (lynparza is given without any other treatment) compared with a physician’s choice of chemotherapy (Capecitabine, Vinorelbine, or Eribulin) in treating metastatic breast cancer patients with BRCA mutations. The study is ongoing but no longer recruiting patients.
OlympiA, another phase III study, is the first PARP inhibitor clinical trial for people with a BRCA 1 or BRCA 2 mutation who have been diagnosed with earlier stage (stage 2 or stage 3) breast cancer. The study will evaluate whether adding the PARP inhibitor olaparib after adjuvant treatment has been completed is safe and improves outcomes. It is currently recruiting patients.